ERBB2 and breast carcinoma: This technology can also produce single-domain antibodies (sdAbs) that target the HER2-tyrosine kinase in HER2-positive breast cancer, exhibiting potential as a therapeutic option by inhibiting kinase activity and reducing cell viability [180].